Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Merck & Co.’s Keytruda is the world’s best ... which is a lot of weight to bear for a tentpole drug teetering on the edge of a patent cliff. That’s why the pharma giant is boosting the ...

These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...

Sen. Elizabeth Warren, D-Mass., questions Robert F. Kennedy Jr., President Donald Trump's pick for Department of Health and Human Services secretary, as he testifies before the Senate Finance ...

“How many of our peers in this industry have been searching for something once a month in Type 2 diabetes?” Griffith said. While investors may stay skeptical, Amgen is advancing. It’s ...

Merck & Co has agreed to pay rival Bristol-Myers Squibb $625 million, plus royalties, to settle a patent case relating to the companies' rival cancer immunotherapies. Merck’s Keytruda ...

The US patent ... that have deferred their launch plans for generics until May or July 2026 depending on the formulation, "or earlier under certain circumstances," according to a Merck statement.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

In extending patent protection for its ... "We now expect to file, have approval, and launch our subcutaneous pembrolizumab in 2025," Davis added, stressing the importance of this advancement. Merck ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck ...